Neurocrine Biosciences Posts Wider Q4 Loss

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) reported a net loss for the fourth quarter of $19.4 million or $0.26 per share, compared to a net loss of $10.6 million or $0.16 per share for the year-ago quarter.

Analysts polled by Thomson Reuters expected the company to report a loss of $0.24 per share for the fourth quarter.

The company did not generate any revenue in the latest quarter.

The company expects to have a gross cash burn, prior to any revenue, of about $80 million to $85 million in 2015. The increase in cash burn from 2014 is mainly due to the expansion and progression of the clinical pipeline, the company said.